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Does Not Affect the Correlation of Preharvest
Hematopoietic Precursor Cell Enumeration with
First-Harvest CD341 Stem Cell Yield
Carlos H. Villa,1 Tsiporah Shore,2 Koen Van Besien,2 Melissa Cushing3The CXCR4 antagonist plerixafor is increasingly used in the mobilization regimens for autologous peripheral
blood stem cell (PBSC) transplantation. This agent may mobilize a different subset of the stem cell population
than traditional regimens, such as growth factors (with and without chemotherapy). Thus, it is important to
determine whether plerixafor has an effect on the utility of measurements used to predict the yield of
CD341 cells, usually either preharvest peripheral blood CD341 enumeration by flow cytometry or hema-
topoietic precursor cell (HPC) enumeration by automated hematology analysis. Although HPC enumeration
has a weaker correlation with first-harvest CD341 cell yield, this parameter still plays an important role in
the timing of apheresis procedures for autologous PBSC transplantation because of its technical simplicity
and low cost. In the present study, we retrospectively examined the correlation of HPC measurements
with CD341 cell yields in patients with multiple myeloma and lymphoma undergoing autologous PBSC trans-
plantation, and investigated how the mobilization regimen affected these results. We found that the corre-
lation coefficients ranged from 0.5877 to 0.7668 and were not significantly impacted by differences in
diagnosis or inclusion of plerixafor in the mobilization regimen. The predictive ability of HPC enumeration
for various target yields was also examined, and receiver-operating characteristic curves were generated. An
HPC cutoff of 20 should result in adequate initial CD341 cell yields (.2.5  106 cell/kg) in .80% of autol-
ogous donors with or without plerixafor. This study confirms the utility of HPC enumeration in prediction of
adequate initial cell yields, and demonstrates that this utility is maintained regardless of whether or not pler-
ixafor is included in the mobilization regimen.
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oi.org/10.1016/j.bbmt.2012.07.002blood aftermobilization.The circulatingHSCs are then
harvested by apheresis, and product yield is quantified
through flow cytometric measurement of CD341 cells
in the apheresis product. There is great interest in
finding efficient ways to predict stem cell yields to
guide important clinical decisions, such as number of
procedures, timing of procedures, and allocation of
clinical resources [3,4].
Agents used for stem cell mobilization include
growth factors (eg, granulocyte macrophage colony-
stimulating factor, granulocyte colony-stimulating
factor [G-CSF]), chemotherapeutic regimens (eg,
etoposide, cytarabine, dexamethasone), and small-
molecule agents targeted at proteins involved in the
maintenance of precursor cells in the bone marrow.
Mobilization regimens typically use these agents ei-
ther alone or in various combinations, and the poten-
tial for higher cell yields are weighed against the risks1867
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monly used mobilization regimens are G-CSF and
G-CSF plus chemotherapy [5]. G-CSF induces
bone marrow hyperplasia, leading to the release of
HSCs into circulation. The addition of chemother-
apy allows for initial induction of bone marrow apla-
sia, which can stimulate hematopoietic recovery when
G-CSF is subsequently administered. This approach
carries significant morbidity, particularly increased
risks of neutropenia and infection.
The risks associated with growth factors and che-
motherapy have spurred the development of more
closely targeted mobilization agents. One successful
example is the small-molecule agent plerixafor, a mac-
rocyclic compound originally developed as a treatment
for HIV, owing to its ability to block CXCR4, a che-
mokine receptor believed to be involved in the binding
of the virus to lymphocytes [6]. CXCR4 is a receptor
for stromal-derived factor 1, a molecule that has che-
motactic activity for lymphocytes and is important in
the homing of hematopoietic stem cells to their niche
in normal adult marrow. Plerixafor’s ability to disrupt
the interaction of CXCR4 with stromal-derived factor
1 has been demonstrated to promote the release of
HSCs from the bone marrow, and plerixafor is now
frequently used in clinical mobilization regimens for
autologous HSCTs [7-9].
Although plerixafor has demonstrated consider-
able clinical benefit in improving CD34 yields and
minimizing the number of apheresis procedures for
autologous PBSC collection, this therapy also may
mobilize a physiologically distinct subset of CD341
HSCs. The proportion of plerixafor-mobilized PBSCs
is thought to be higher in the G1 phase of the cell cy-
cle, and there is speculation that plerixafor may mobi-
lize a more primitive subset of progenitor cells and
possibly a more potent CD341/CD382 cell popula-
tion [10,11]. Others have reported that plerixafor
also may be capable of mobilizing dormant leukemic
stem cells, thereby removing them from the
protective niche in the bone marrow and sensitizing
them to chemotherapy [12], again confirming plerixa-
for’s ability to mobilize distinct populations of cells
compared with growth factors and chemotherapy.
Regardless of the mobilization regimen, the yield is
quantified by the number ofCD341 cells in the apheresis
product. CD34, a cell surface sialomucin involved in
adhesion, is the most commonly accepted marker for
HSCs. The relationship between CD341 cell dose and
successful engraftment has been widely explored, and
the correlations between the transfused CD341 cell
dose and the likelihood of successful engraftment and
the duration of recovery time are now commonly ac-
cepted [13,14]. The dose of CD341 cells required for
rapid, sustained engraftment is presently believed to be
at least 2  106 cells/kg, although the optimal number
may be higher, with some studies suggesting a range of4-6  106 CD341 cells/kg [15,16]. Thus, a key step
in the transplantation process is the collection of
sufficient numbers of CD341 cells to achieve an
optimal PBSC dose. This has led to a focus on
determining the optimal timing of apheresis procedures
for collecting PBSCs to maximize CD341 yields.
Unnecessary apheresis procedures not only result in
significant morbidity in donors, but also incur increased
financial and resource costs for transplantation centers.
These challenges have resulted in great interest in
simple diagnostic techniques that can be used to predict
CD34 yields and optimum timing of apheresis.
The measurement of preharvest peripheral
CD341 cells through flow cytometry is highly corre-
lated with the first-harvest yield of CD341 cells
[17,18], and many transplantation centers use this
parameter to optimally plan timing of collections,
clinical scheduling, and collection volumes. Although
preharvest CD341 cell measurement has been
validated as a useful measure in predicting PBSC
yields, the use of this test is hindered by the high
cost, lengthy duration, and technical expertise
required for flow cytometry techniques. One
alternative to preharvest CD341 measurement is the
use of WBC counts as an indicator of bone marrow
recovery to determine when to initiate apheresis.
However, WBC counts have correlated poorly with
product CD34 cell yields across several studies [18,19].
Another alternative approach to predicting first-
harvest PBSC yield is the use of a hematology analyzer
that identifies a population of immature hematopoietic
precursor cells (HPCs) according to size, density, and
differential lysis resistance [20]. Several studies found
thatHPC enumeration with an automated hematology
analyzer (Sysmex, Mundelein, IL) was correlated with
the yield of CD341 cells collected by apheresis and
used HPC count to predict the initiation of collection
[19,21,22]. Although studies have demonstrated that
HPC is an inferior predictor to peripheral CD341
counts by flow cytometry [23], HPC enumeration is
far quicker (usually \3 minutes) and less costly, re-
quires less technical expertise, and can be performed
as part of routine complete blood count analysis.
Thus, it remains a clinically valuable tool for planning
stem cell collection.
HPC measurements depend on the differential ly-
sis resistance of HPCs. This differential resistance is
believed to be a product of the differing phospholipid
composition of cell membranes at the various stages of
hematopoietic cell maturation [24]. Although this
measure is a rough approximation of cells in early
stages of maturation, it may be vulnerable to a number
of interfering factors in clinical practice. One question
that remains unclear is whether the use of mobilization
agents, especially plerixafor, has an impact on the cor-
relation between HPC and CD34 cell yields. As noted
previously, plerixafor may mobilize physiologically
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degree of maturation and membrane composition, in
addition to cell markers. Thus, this mobilized cell pop-
ulation may ultimately behave differently in HPC
analyses. To this point, little data have been available
to explore this question, and whether HPCs as a pre-
dictor of CD341 cell yield in stem cell collection is
affected by the inclusion of plerixafor in the mobiliza-
tion regimen remains unclear. In the present study,
we retrospectively examined data from autologous
HSCTs performed at our institution over a period of
22 months to investigate how the inclusion of plerixa-
for in mobilization regimens affected the predictive
ability of HPC measurement for CD341 cell yields
in patients undergoing initial PBSC collection for
autologous HSCT.PATIENTS AND METHODS
Patient Population and Study Design
In the present study, we retrospectively examined
data fromall autologousHSCTsperformed at our hospi-
tal between January 2010 andOctober 2011. Patients in-
cluded in the study were all patients undergoing
autologousHSCTatourmedical centerwithfirst harvest
between January2010andOctober2011.Patientdiagno-
ses includedmultiple myeloma, Hodgkin’s disease, man-
tle cell lymphoma, follicular lymphoma, diffuse large B
cell lymphoma, T cell lymphomas, and other non-
Hodgkin lymphomas, plus 1 patient with a testicular
germ cell tumor. The germ cell tumor was included
with the lymphoma group in all analyses. Mobilization
regimens were G-CSF alone, G-CSF plus plerixafor,
G-CSF plus a chemotherapy regimen, or a combination
ofG-CSF, chemotherapy, and plerixafor.Chemotherapy
regimens used formobilization included dexamethasone,
ifosfamide, cisplatin, etoposide (DICE), rituximabDICE
(RDICE), dexamethasone, cytarabine, cisplatin (DHAP),
dexamethasone, cyclophosphamide, etoposide, cisplatin
(DCEP), and cytarabine, among others. Mobilization
regimens were confirmed by electronic medical record
review. Clinical case histories were reviewed from the
last documented office visit before mobilization, and de-
mographic data (eg, age, sex, weight, diagnosis) were col-
lected from this documentation. Preharvest peripheral
complete blood count, HPC, and apheresis product
data were collected from patient records maintained in
the cellular therapy laboratory.Enumeration of HPCs and CD341 Cells
Enumeration of HPC was performed using a Sys-
mex XE-5000 hematology analyzer. HPCs were iden-
tified in the immature information channel, using
radiofrequency and direct current methods to measure
cell size and density, as well as differential lysis resis-tance using a proprietary lytic reagent. This technique
preferentially lyses mature leukocytes over immature
cells based on differences in cell membrane phospho-
lipid composition [20]. HPCs were reported as the
number of cells per microliter in the peripheral blood
before initial PBSC collection. The quantity of
CD341 cells in the apheresis products were deter-
mined by standard flow cytometry analysis techniques
using Stem-Kit reagents (Beckman Coulter, Brea, CA)
on a FACSCalibur instrument (BD Biosciences, Palo
Alto, CA). A dual-platform modified International
Society for Hematotherapy and Graft Engineering
protocol was used to determine the absolute CD341
cell count in the product.
PBSC Collection
Collection of PBSCs was performed using the
COBE SPECTRA Apheresis System 7.0 (Terumo
BCT, Lakewood, CO). Each patient undergoing col-
lection had an apheresis catheter inserted, and collec-
tion was performed using large-volume apheresis
(18-24 L) in accordance with standard protocol. An
algorithm determined when to start apheresis and
when to add Mozobil (Genzyme, Bridgewater, NJ) to
optimize mobilization (see Supporting Information).
Statistical Analysis
Patient characteristics, such as age, weight, and
sex, are presented with descriptive statistics, such as
median and range. Distributions of data were analyzed
using theD’Agostino-Pearson omnibus normality test.
Correlation analyses were performed using the Spear-
man rank test for nonparametric data. Linear regres-
sion models were fitted to the logarithm of the
number of first-harvest CD341 cells (cells/kg) plotted
against the logarithm of the HPCs in preharvest
peripheral blood (cells/mL). Apheresis product data
were grouped into 3 categories of harvest yield: poor
(0.0-2.5  106 cells/kg), medium (2.5-10  106 cells/
kg), and high (.10  106 cells/kg).
Receiver-operating characteristic (ROC) curve
analyses were performed to evaluate the ability of
HPC count to predict target CD341 cell yield. ROC
curves were generated for HPC count as a predictor
of poor CD341 cell yield (\2.5  106 cells/kg), ade-
quate initial CD341 cell yield (.5  106 cells/kg),
and high CD341 cell yield (.10  106 cell/kg). Area
under the ROC curve (AUC) and confidence intervals
(CIs) were calculated by a nonparametric method.
These analyses allowed for comparison of the predic-
tive accuracy of HPCs for CD341 cell yield, genera-
tion of sensitivity and specificity trade-off curves, and
determination of optimum thresholds. Statistical anal-
yses were performed using GraphPad Prism version
5.0 data analysis software (GraphPad Software, San
Diego, CA).
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Patient Characteristics and Mobilization
Regimens
Patient characteristics are summarized in Table 1.
A total of 128 patients underwent PBSC harvest proce-
dures at our institution during the study period: 45
patients with a diagnosis of lymphoma and 83 with
multiple myeloma. Among the lymphomas, diffuse
large B cell lymphomawas themost frequent diagnosis,
followed by Hodgkin’s disease. Eighty-four of the 128
patients received a mobilization regimen that included
plerixafor, and the other 44 patients were mobilized
with G-CSF alone or G-CSF plus chemotherapy.
One patientwasmobilizedwith plerixafor alone, owing
to a history of anaphylactic reaction to G-CSF. In the
patients receiving plerixafor, the drugwas normally ad-
ministered on the evening before HPC enumeration
and HSC collection. A diagnosis of multiple myeloma
was predominant in the patients who received plerixa-
for. Seventy-four of the 128 patients (57.8%) went on
to require additional apheresis procedures after the ini-
tial collection. The whole cohort had a median age of
57.9 years (median, 61.5 years) and a slight predomi-
nance of males (53.9%).Correlation of PBSC Counts and CD341 Cell
Yields
Examination of median initial HPCmeasurements,
CD34 cell yields, age, and weight showed similarities in
the patients with and without plerixafor mobilization;
these data are summarized in Table 1. We further
analyzed the distribution of CD34 cell yields by group-
ing patients into low-, medium-, and high-yield groups
(Table 2). Low yield was defined as\2.5 106 cells/kg
on initial harvest;medium yield, as 2.5-10 106 cells/kg
on initial harvest; and high yield, as.10  106 cells/kg
on initial harvest. Our results demonstrated that most
patients had a medium-yield harvest, with roughly
one-quarter of patients having a poor initial CD34 cellTable 1. Patient Characteristics and Cell Counts in Apheresis Prod
All Patients
Number of patients 128
Age, years, median (range) 61.5 (21-76)
Weight, kg, median (range) 77.6 (39.0-145.2
Sex, M:F, n 69:59
Diagnoses, n
Hodgkin’s disease 8
Mantle cell 3
Diffuse large B cell 18
Follicular 7
T cell lymphoma 5
Other 4
Multiple myeloma 83
Preharvest peripheral blood, HPCs, cells/mL,
median (range)
32 (0-673)
Apheresis product CD34+ cell yield, 106 cells/
kg, median (range)
6.08 (0.16-43.97yield. When we separated this analysis by diagnosis
(lymphomas versus multiple myelomas), these distribu-
tions were similar regardless of diagnosis (see Support-
ing Information).
In our analysis of HPC counts and CD34 cell
yields, the data did not fall in a normal distribution
by the D’Agostino-Pearson test. Consequently, the
correlation between HPC and first-harvest CD341
cell yield was performed on the untransformed data us-
ing the Spearman rank test for nonparametric data.
The results of the correlation analyses of the untrans-
formed data are summarized in Table 3. To perform
linear regression analyses, the data were transformed
using a log-log algorithm, with the transformed data
and best-fitting curves presented on a log-log scale
(Figure 1). The Spearman r correlation coefficient
for all patients was 0.7126 (95% CI, 0.6118-0.7905)
and did not differ significantly between the patients
who received plerixafor mobilization (r 5 0.7367;
95% CI, 0.6163-0.8235) and those who did not
(r 5 0.6831; 95% CI, 0.4775-0.8178). There was
also no significant difference in correlation coefficients
by diagnosis; the correlation coefficient was 0.6958
(95% CI, 0.5595-0.7955) for all patients with multiple
myeloma and 0.7342 (95% CI, 0.5555-0.8480) for all
patients with lymphoma. The overall range of correla-
tion coefficients of 0.5877-0.7668 is in good agree-
ment with previous studies examining the correlation
of HPC count and CD34 yield reporting correlation
coefficients largely in the range of 0.5-0.7 [19,21,25].Predictive Value of HPCs in Preharvest
Peripheral Blood
We further analyzed the predictive value of HPC
count in our study population by examining the posi-
tive predictive value (PPV) and negative predictive
value (NPV) for CD341 cell collection targets of
1  106 cells/kg and 2.5  106 cells/kg, using HPC
thresholds of 5, 20, 50, and 80 cells/mL (Table 4).
These collection targets were chosen to representucts and Preharvest Peripheral Blood
With Plerixafor Without Plerixafor
84 44
62 (22-76) 55 (21-73)
) 79.6 (41.7-145.2) 73.3 (39-116.5)
48:36 21:23
4 4
1 2
5 13
3 4
3 2
2 2
66 17
34 (0-520) 27 (0-673)
) 6.12 (0.16-43.97) 5.78 (0.21-34.10)
Table 2. Distribution of CD34+ Cell Yields by Mobilization
Regimen, All Diagnoses
Mobilization Regimen
Initial CD34 Cell Yield,  106 Cells/kg
n
Low
(0-2.5)
Medium
(2.5-10)
High
(>10)
Without plerixafor, n (%) 14 (31.8%) 17 (38.6%) 13 (29.5%) 44
G-CSF alone 5 (22.7%) 12 (54.5%) 5 (22.7%) 22
G-CSF + chemotherapy 9 (40.9%) 5 (22.7%) 8 (36.4%) 22
With plerixafor, n (%) 20 (23.8%) 38 (45.2%) 26 (31.0%) 84
G-CSF + plerixafor 16 (21.3%) 35 (46.7%) 24 (32.0%) 75
G-CSF + chemotherapy
+ plerixafor
4 (50.0%) 3 (37.5%) 1 (12.5%) 8
Plerixafor only 0 (0.0%) 0 (0.0%) 1 (100.0%) 1
All regimens, n (%) 34 (27%) 55 (43%) 39 (30%) 128
CD34+ cell yields are grouped as low yield (0-2.5  106 cells/kg), me-
dium yield (2.5-10  106 cells/kg), or high yield (>10  106 cells/kg)
products.
Table 3. Spearman r Coefficients for Correlation between
HPC Enumeration and First-Harvest CD34+ Cell Yield
Diagnosis All Patients With Plerixafor Without Plerixafor
Lymphoma n 5 45 n 5 18 n 5 27
Spearman r 0.7342 0.6918 0.7668
95% CI 0.5555-0.8480 0.3187-0.8793 0.5373-0.8905
Multiple myeloma n 5 82 n 5 66 n 5 17
Spearman r 0.6958 0.7213 0.5877
95% CI 0.5595-0.7955 0.5758-0.8226 0.1339-0.8378
All diagnoses n 5 128 n 5 84 n 5 44
Spearman r 0.7126 0.7367 0.6831
95% CI 0.6118-0.7905 0.6163-0.8235 0.4775-0.8178
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collection. For HPC counts $80 cells/mL, all patients
had CD341 cell yields exceeding the higher target of
2.5 106 cells/kg, regardless of diagnosis or mobiliza-
tion regimen. At a HPC threshold of $50 cells/mL,
only 1 patient failed to collect.2.5  106 cells/kg, re-
sulting in a PPV of 0.98 for all patients (1.00 for
patients receiving plerixafor, 0.94 for those without
plerixafor) for the collection target. When the HPC
threshold was lowered to 20 cells/mL, the PPV for
the 2.5  106 cells/kg target remained relatively
strong, at 0.92 for all patients (0.92 for patients receiv-
ing plerixafor, 0.92 for those without plerixafor).
When the HPC threshold was lowered to $5 cells/
uL, there was a further dropoff in PPV for theFigure 1. The relationship between first-harvest CD341 cell yield and initial p
open circles; those who did not receive plerixafor, by crosses. Shown are the d
regimens before initial harvest (A), all patients who did not receive plerixafor as
with multiple myeloma (C), and all patients with lymphoma (D).2.5  106 cells/kg target to 0.87 (0.86 for patients re-
ceiving plerixafor, 0.83 for those without plerixafor).
At the HPC threshold of 5 cells/uL, we also observed
the first patients who met the HPC threshold who
failed to collect .1  106 cells/kg, with the PPV for
this target dropping from 1.00 to 0.96 for all patients
(0.99 for patients receiving plerixafor, 0.94 for those
without plerixafor).
In our study cohort, HPC enumeration was also
useful as a predictor of poor CD341 cell yield, as
reflected in the analyses of NPVs. In all patients with
an HPC count\5 cells/uL, the NPV for a collection
target of 1  106 cells/kg was 0.78 (0.80 for patients
receiving plerixafor, 0.75 for those without plerixafor).
The NPV of HPC\5 cells/mL for a collection target
of 2.5  106 cells/kg was improved to 0.94 for all
patients (1.00 for patients receiving plerixafor, 0.88
for those without plerixafor).
To better characterize the predictive value of HPC
count for CD341 cell yield, and better define thereharvest HPC count. Patients who received plerixafor are designated by
ata for all patients who received plerixafor as part of their mobilization
part of their mobilization regimens before initial harvest (B), all patients
Table 4. PPVs and NPVs of Various HPC Cutoff Values for Target CD34+ Cell Yields of 1  106 Cells/kg and 2.5  106 Cells/kg
Cutoff Value of HPCs, Cells/mL
PPV NPV
HPC > Cutoff Yield > Target PPV HPC < Cutoff Yield < Target NPV
Target of 1  106 CD34+ cells/kg
80 31 31 1.00 97 15 0.15
50 49 49 1.00 79 15 0.19
20 79 79 1.00 49 15 0.31
5 110 106 0.96 18 14 0.78
Target of 2.5  106 CD34+ cells/kg
80 31 31 1.00 97 33 0.34
50 49 48 0.98 79 33 0.42
20 79 73 0.92 49 28 0.57
5 110 96 0.87 18 17 0.94
Target of 1  106 CD34+ cells/kg
80 19 19 1.00 65 6 0.09
50 33 33 1.00 51 6 0.12
20 53 53 1.00 31 6 0.19
5 74 73 0.99 10 8 0.80
Target of 2.5  106 CD34+ cells/kg
80 19 19 1.00 65 20 0.31
50 33 33 1.00 51 20 0.39
20 53 49 0.92 31 16 0.52
5 74 64 0.86 10 10 1.00
Target of 1  106 CD34+ cells/kg
80 12 12 1.00 32 9 0.28
50 16 16 1.00 28 9 0.32
20 26 26 1.00 18 9 0.50
5 36 34 0.94 8 6 0.75
Target of 2.5  106 CD34+ cells/kg
80 12 12 1.00 32 14 0.44
50 16 15 0.94 28 13 0.46
20 26 24 0.92 18 12 0.67
5 36 30 0.83 8 7 0.88
Data are presented for all patients, all patients mobilized with a regimen that included plerixafor, and all patients mobilized without plerixafor.
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tial collections, we constructed ROC curves for the
dataset. The results of these analyses are summarized
in Figure 2. The AUC represents the system’s accu-
racy, with an AUC of 1.0 indicating a perfect test and
an AUC of 0.5 indicating a test with no benefit over
random choice. Figure 2 presents the results of ROC
analyses for prediction of poor collection (CD341
cell yield\2.5  106 cells/kg). The AUC was 0.8927
(95% CI, 0.8276-0.9577) for all patients, 0.8943
(95% CI, 0.8151-0.9735) for patients who received
plerixafor, and 0.8845 (95% CI, 0.7720-0.9971) for
patients without plerixafor. Thus, the inclusion of
plerixafor in the mobilization regimen did not impact
the accuracy of HPC as a predictor for an initial collec-
tion yield\2.5 106cells/kg.We also translated these
data into curves demonstrating the trade-off between
specificity and sensitivity (Figure 2B).
We performed similar analyses for the prediction
of an initial collection yield .5  106 cells/kg, a com-
mon clinical collection target for patients undergoing
autologous HSCT with PBSCs. The AUC for predic-
tion of a .5  106 cells/kg yield was 0.8410 (95% CI,
0.7698-0.9122) for all patients, 0.8788 (95% CI,
0.8012-0.9564) for patients who received plerixafor,
and 0.7847 (95%CI, 0.6473-0.9221) for patients with-
out plerixafor. Although there was again no significantdifference among the groups, the AUC for prediction
of .5  106 cells/kg in patients who did not receive
plerixafor was lower with a wide confidence interval.
The AUCs for prediction of .5  106 cells/kg were
lower for all groups analyzed, although there was again
overlap of the CIs.
This result led us to perform further AUC analyses
to examine HPC count as a predictor of high initial
CD341 cell yield (.10  106 cells/kg). The AUC for
prediction of .10  106 cells/kg yield was 0.8623
(95% CI, 0.7947-0.9299) for all patients, 0.8465
(95% CI, 0.7567-0.9362) for patients who received
plerixafor, and 0.8859 (95%CI, 0.7816-0.9901) for pa-
tients without plerixafor. Our ROC analyses suggest
that HPC enumeration may be more accurate in pre-
dicting a poor or high initial yield than the ability to dif-
ferentiate donors with yields in the intermediate range
near 5 106 cells/kg. In the present study, however, we
found no significant difference in the predictive ability
of HPC between patients who did and did not receive
plerixafor as part of their mobilization regimens.DISCUSSION
When harvesting PBSCs for autologous HSCT,
mobilization of PBSCs and the timing of collection
through apheresis are critical steps in achieving cell
Figure 2. ROC curves (A) and the trade-off between sensitivity and specificity of HPC count as a predictor of CD341 cell yield\2.5 106 cells/kg and
as a predictor of initial CD341 cell yield .5  106 cells/kg (B). AUCs, shown in the inset of each ROC plot, did not differ significantly among the
mobilization regimens, based on the 95% CI for each AUC.
Biol Blood Marrow Transplant 18:1867-1875, 2012 1873Plerixafor’s Effect on Preharvest HPCdoses that result in reliable and rapid hematopoietic
engraftment and recovery. The introduction of novel
mobilization agents, such as plerixafor, promises major
improvements in CD341 cell yields, minimizes the
number of apheresis collections, and ultimately
reduces morbidity in patients. The increasing use ofplerixafor in clinical settings makes it important to
understand how its mobilization pathways can impact
the correlation of clinical diagnostic techniques used
to predict CD341 cell yields. The most useful of
such techniques continue to be preharvest peripheral
CD341 cell count and HPC enumeration through
1874 Biol Blood Marrow Transplant 18:1867-1875, 2012C. H. Villa et al.automated hematology analysis that identifies HPCs
through size, density, and differential lysis resistance.
We examined how this latter measurement can be af-
fected by the addition of plerixafor to the mobilization
regimen in autologous donors.
Our results confirm the ability of HPC measure-
ment to predict CD341 cell yields and identify
a correlation between these values similar to that re-
ported in previous studies, with correlation coeffi-
cients ranging from 0.5877 to 0.7668, depending
on diagnosis and mobilization regimen. Importantly,
these correlation coefficients were not significantly
affected by the use of plerixafor in PBSC mobiliza-
tion. The correlation was also independent of diag-
nosis, with similar data in patients diagnosed with
lymphoma and patients with multiple myeloma.
We further examined the predictive ability of HPC
measurement and found that an HPC cutoff of 20
cells/mL was able to predict an initial collection of
.2.5  106 cells/kg with a 92% PPV in our study
population. Note that this estimate depends on the
study population accurately reflecting the true prev-
alence of poor collectors.
We performed a more extensive analysis of the ac-
curacy of HPC count as a predictive diagnostic tech-
nique through the generation of ROC curves. These
analyses demonstrated that the AUC value, which cor-
relates with the predictive accuracy of HPC count, was
not significantly affected by the addition of plerixafor
to the mobilization regimen. Although AUCs were
maximized in the ability to predict poor yields
(\2.5  106 CD34 cells/kg) and high yields
(.10  106 CD34 cells/kg), they suggest that HPC
count may be less reliable as a predictive measure for
intermediate yields (.5  106 cells/kg). Based on our
ROC analyses, the calculated specificity and sensitivity
for prediction of poor initial collection (\2.5  106
cells/kg) using an HPC threshold of 20 cells/mL are
78% (95% CI, 65%-93%) and 82% (95% CI, 68%-
86%), respectively. If the HPC threshold of 20 cells/
mL were established as the sole clinical criterion for
initiation of stem cell collection, then approximately
80% of true ‘‘poor collectors’’ would be identified be-
fore initiation of apheresis. Likewise, 80% of true
‘‘good collectors’’ would actually proceed with collec-
tion. With a PPV of 92%, only approximately 8% of
patients who do initiate collection will have an inade-
quate initial yield (\2.5  106 cell/kg). Given the
high cost of stem cell collection, some institutions
may want to avoid the 8% of collections with poor
yields and use a higher HPC threshold. Alternatively,
institutions could confirm the timing of apheresis at
lower HPC levels by also performing CD34 cell anal-
ysis by flow cytometry. In the present study, we also
provided curves demonstrating the trade-off between
the NPV and PPV of HPC cutoffs as predictors for
target CD34 cell yields.Overall, although the present study confirms the
utility of HPC count in patients receiving plerixafor,
it also demonstrates the shortcomings of this para-
meter in predicting CD34 cell yields. There remains
no quick and simple way to always predict the optimal
timing for stem cell collection. Fortunately, our results
also demonstrate that the addition of plerixafor to mo-
bilization regimens has not complicated the situation
any further. Our findings indicate thatHPC count cor-
relates just as well in patients receiving plerixafor as in
those receiving other mobilization regimens.ACKNOWLEDGMENTS
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